Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients

• Egile Nagusiak: Peng Cao (Egilea), Wei Guo (Egilea), Jun Wang (Egilea), Sanlan Wu (Egilea), Yifei Huang (Egilea), Yang Wang (Egilea), Yani Liu (Egilea), Yu Zhang (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The purposes of this study were to identify physiological and genetic factors that contributed to variability of pemetrexed (PEM) exposure and to optimize the dosing regimens for Chinese non-small cell lung carcinoma patients. A prospective population pharmacokinetics (PPK) research was performed in...